Treatment of glioblastoma has remained uniformly deadly for over two decades. Now a drug being developed at Canada’s McMaster University shows early promise as a treatment for the brain cancer. That phrase, early promise, is key. Authors writing in the journal Science Translational Medicine, say the newly developed drug can eliminate glioblastoma tumors, which typically resist standard treatment and recur rapidly, even after surgery, radiation and chemotherapy. This possible new treatment reprograms the body’s own immune system to recognize and attack a specific protein found on the surface of glioblastoma cells. Lead investigator, Sheila Singh, says discussions are already underway to move the research toward clinical trials.